CB-708

Feb. 24, 2026 -- Antengene Corporation Limited ( "Antengene", SEHK: 6996.HK) , a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune diseases, solid tumors and hematological malignancies, announced that it has entered into a clinical collaboration agreement with Shanghai Junshi Biosciences Co., Ltd ("Junshi Biosciences", SEHK: 1877.HK; SSE: 688180). Under the collaboration, the parties will jointly evaluate the synergistic therapeutic potential of Antengene's ATG-037, an oral small-molecule CD73 inhibitor, in combination with Junshi Biosciences' JS207, a recombinant humanized anti-PD-1/VEGF bispecific antibody, in patients with solid tumors in Mainland China, with the goal of identifying clinical signals across multiple tumor types. This collaboration builds on the encouraging Phase I proof-of-concept clinical data generated with ATG-037. At a time when resistance to checkpoint inhibitors (CPIs) has become a major clinical challenge, the Phase I study evaluating ATG-037 in combination with CPIs has already demonstrated promising potency into reversing CPI resistance. Beyond validating the synergistic potential of these two innovative drugs, this collaboration aims to advance the efficacy of existing immunotherapies and extend the overall survival (OS) of cancer patients through a "triple-axis" approach that incorporates immune checkpoint signalling, anti-angiogenesis, and the alleviation of adenosine-mediated immunosuppression. ATG-037, Antengene's orally administered small-molecule CD73 inhibitor, offers significant advantages over anti-CD73 monoclonal antibodies. In preclinical studies, ATG-037 demonstrated stronger inhibition of cell-surface CD73 enzymatic activity and overcame the "hook effect" commonly observed with antibody-based approaches. In addition, ATG-037's higher tissue penetration compared with antibodies may facilitate complete CD73 inhibition at the cellular level. ATG-037 has demonstrated encouraging clinical activity in combination with anti–PD-1 therapy in patients with CPI-resistant melanoma and non-small cell lung cancer (NSCLC), based on the latest data presented at Antengene's R&D Day in November 2025. In the ongoing Phase I/Ib STAMINA-01 study, the combination achieved an objective response rate (ORR) of 33.3% with a disease control rate (DCR) of 100% in patients with CPI-resistant melanoma, and an ORR of 21.4% with a DCR of 71.4% in patients with CPI-resistant NSCLC. The dataset was generated in Australia in patients with CPI-refractory solid tumors, with pembrolizumab and/or nivolumab as the predominant prior anti–PD-1 therapies, and more than 70% of melanoma patients were refractory to both anti–PD-1 and anti–CTLA-4 (ipilimumab). These results support ATG-037's clinically meaningful activity across multiple tumor types, particularly in patients with prior immunotherapy resistance. Importantly, ATG-037 has demonstrated a favorable safety and tolerability profile in combination treatment, with no new or unexpected safety signals observed, including in patients receiving long-term therapy.Grade 3 or higher treatment-related adverse events only occurred in 7.9% of patients. Responses have also shown encouraging durability, including a patient who achieved a complete response and has remained on study for over three years and is currently receiving ATG-037 monotherapy for more than a year, as well as multiple patients with durations of response exceeding 12 months. These data support ATG-037's potential role as a backbone agent for next-generation immuno-oncology combination regimens. JS207, Junshi Biosciences' independently developed recombinant humanized anti-PD-1/VEGF bispecific antibody, has demonstrated promising anti-tumor activity and a manageable safety profile in both preclinical and clinical studies. JS207's preclinical studies demonstrated its robust anti-tumor efficacy in multiple tumor models and supported a differentiated mechanism of action, with VEGFA shown to enhance JS207's antigen binding activity, T-cell activation potency and internalization of cell-surface PD-1. In a poster presented at ESMO Asia 2025, JS207 monotherapy showed encouraging efficacy across solid tumors. 62 patients with PD-L1 positive NSCLC received JS207 monotherapy as first-line treatment, and achieved an ORR of 58.1% and a DCR of 87.1%. Clinical activity has also been observed in additional tumor types, including hepatocellular carcinoma (HCC) and renal cell carcinoma (RCC), supporting the potential of PD-1/VEGF dual targeting across multiple tumor settings. To date, JS207 has 11 ongoing phase II clinical studies, exploring its use in combination with chemotherapy, monoclonal antibodies, antibody-drug conjugates (ADCs) and other drugs in NSCLC, colorectal cancer, triple-negative breast cancer, liver cancer and other tumor types, with nearly 500 patients enrolled. Based on the accumulated data from these studies, the U.S. Food and Drug Administration (FDA) has approved the investigational new drug (IND) application, allowing Junshi Biosciences to initiate an open-label, two-arm, randomized, active-controlled, Phase II/III clinical study comparing JS207 to nivolumab for the neoadjuvant treatment of patients with stage II/III, resectable, actionable genomic aberration (AGA)-negative NSCLC. The scientific rationale for the collaboration is based on the complementary and potentially synergistic mechanisms of CD73 inhibition and dual PD-1/VEGF targeting. CD73 is recognized as a key regulator of immune suppression and angiogenesis within the tumor microenvironment through the generation of adenosine, which can dampen anti-tumor immune responses. In both clinical and preclinical settings, CD73 inhibitors have demonstrated meaningful synergy with anti–PD-1 monoclonal antibodies. In addition, CD73 activity has been shown to promote angiogenesis, including through upregulation of VEGF signaling, and may contribute to the development of resistance to anti-VEGF therapies. Given the broad relevance of immune suppression, angiogenesis and adenosine signaling across solid tumors, this combination strategy has the potential to be applicable across multiple tumor types. Taken together, these observations suggest that combining CD73 blockade with PD-1/VEGF-directed approaches has the potential to enhance and sustain therapeutic effects. Together, the combination of ATG-037 with JS207 represents a potential "triple-axis" approach that simultaneously modulates immune checkpoint signaling, angiogenesis, and the adenosine pathway. With the potential to deepen responses while maintaining a favorable safety profile, the combination of ATG-037 with JS207 may further improve the durability of benefit and may translate into improved OS. We look forward to working closely with Junshi Biosciences and leveraging our respective expertise in target biology and clinical development to accelerate the evaluation of ATG-037 in combination with JS207 across multiple solid tumor types, with the goal of identifying clinical signals and delivering more innovative treatment options for patients in Mainland China. Antengene Corporation Limited ( "Antengene", SEHK: 6996.HK) is a global, R&D-driven, commercial-stage biotech company focused on developing first-in-class/best-in-class therapeutics for diseases with significant unmet medical needs. Its pipeline spans from preclinical to commercial stages and includes several in-house discovered programs, including ATG-022 (CLDN18.2 ADC), ATG-037 (oral CD73 inhibitor), ATG-101 (PD-L1 x 4-1BB bispecific antibody), ATG-031 (CD24-targeting macrophage activator), and ATG-042 (oral PRMT5-MTA inhibitor). Antengene has also developed AnTenGager™, a proprietary T cell engager 2.0 platform featuring "2+1" bivalent binding for low-expressing targets, steric hindrance masking, and proprietary CD3 sequences with fast on/off kinetics to minimize cytokine release syndrome (CRS) and enhance efficacy. These characteristics support the platform's broad applicability across autoimmune disease, solid tumors and hematological malignancies indications. To date, Antengene has obtained 32 investigational new drug (IND) approvals in the U.S. and Asia, and submitted new drug applications (NDAs) in 11 Asia Pacific markets. Its lead commercial asset, XPOVIO® (selinexor), is approved in Mainland of China, Taiwan China, Hong Kong China, Macau China, South Korea, Singapore, Malaysia, Thailand, Indonesia and Australia, and has been included in the national insurance schemes in five of these markets (Mainland of China, Taiwan China, Australia, South Korea and Singapore). The content above comes from the network. if any infringement, please contact us to modify.

1、月球南极水冰研究 中国有重大突破！为嫦娥七号做准备快科技2月25日消息，我国计划于2026年前后发射嫦娥七号(CE-7)月球探测器，目标直指月球南极-艾特肯盆地，探测月球南极的水冰资源，其存在与否对未来月球基地的选址与建设至关重要。CE-7探测任务的候选着陆区临近月球南极的沙克尔顿撞击坑，而其重要科学任务之一是开展月球南极水冰的高精度遥感和就位探测。水冰（热）稳定性反映的是在长期、地质时间尺度上水冰升华损失的难易程度。评价水冰的稳定性对于了解水冰在月球极区的分布特征意义重大。尤其对于CE-7的南极水冰就位探测任务，水冰稳定性的研究可以指导探测，有助于确定更有可能保存水冰的区域。http://finance.sina.com.cn/tech/roll/2026-02-25/doc-inhnzrtk5117788.shtml2、三生国健：重组抗IL-4Rα人源化单克隆抗体注射液新药上市申请获得受理三生国健公告，近日，公司产品重组抗IL-4Rα人源化单克隆抗体注射液（研发代码：SSGJ-611）的新药上市申请（NDA）获得受理。SSGJ-611是公司自主研发设计、筛选并人源化的抗IL-4Rα单克隆抗体，具有全新的氨基酸序列。SSGJ-611能够通过特异性的结合IL-4Rα，阻断IL-4和IL-13的信号传导达到缓解特应性皮炎等疾病的作用。http://k.sina.com.cn/article_5953189932_162d6782c06703ucke.html3、就在元宵节！北京可赏月全食元宵佳节将至，一场月全食将在当晚上演。北京天文馆专家表示，这是本年度我国境内可见的头号天象，非常值得期待。本次月食初亏发生于3月3日17时49分，此时，只有东北地区能够在地平线之上看到月亮。18时22分，月亮被“吃掉”一半，包括北京在内的东部地区将在此前后迎来带食月升。19时4分食既，月亮完全进入本影，红月亮取代了满月，夜空重归暗色，被满月光辉掩盖的恒星们也将一一显现。食甚发生在19时33分，月亮最暗，之后月亮将越来越亮。20时2分生光，全食阶段结束，月亮开始重新显露白色的光芒。此后的一个多小时里，月亮黑色的缺口逐渐变小，直到21时17分复圆，月亮完全恢复为饱满的圆盘。http://finance.sina.com.cn/jjxw/2026-02-25/doc-inhnzrtk5117753.shtml4、中国科学院收紧 APC 报销政策，Nature Communications 等 30 多本高价期刊受影响IT之家 2 月 25 日消息，《Science》当地时间 2 月 24 日发文，称中国科学院正计划对科研论文版面费支出作出重大调整。受影响期刊包括 Nature Communications、Cell Reports 和 Science Advances 等。作为全球规模最大的科研机构之一，中国科学院已通知所属科研人员，拟自 3 月 1 日起停止使用院内经费支付 30 多本国际高收费开放获取期刊的论文处理费（APC）。中国科学院拥有约 5 万名科研人员、下设约 100 家研究机构。多名科研人员表示已收到来自所在单位管理层的政策草案通知。http://finance.sina.com.cn/tech/digi/2026-02-25/doc-inhnzvzh5002854.shtml5、《鸟墙》：以真鸟大小画下一场跨越3.75亿年的演化之旅2003年的春天，美国康奈尔鸟类学实验室正式入驻新的大楼。这座设计大胆的现代建筑一侧有一个挑高3层的开放空间，被预订作为访客中心——它的外观独特又摩登，但是，一片面积达230多平方米的空白墙面也因为其别样的几何形状而被割裂了出去。当建筑逐渐成形、人们开始频繁进出，在如此层高的通透空间之中，这面最初被均一刷成橄榄绿色的墙壁，越发显得突兀。时任实验室主任的约翰·W.菲茨帕特里克一直很想解决这个空白难题，想以此版面赞颂鸟类的演化与多样性。http://k.sina.com.cn/article_1644114654_61ff32de020023w7y.html6、元宵夜将上演本年度唯一月全食新京报记者 张璐 编辑 刘梦婕 校对 李立军今年元宵节是3月3日，本年度唯一一次月全食将于当天傍晚上演，届时，一轮“红月”将悬挂夜空。北京天文馆专家表示，本次月食初亏发生于3月3日17时49分，此时只有东北地区能够在地平线之上看到月亮。18时22分，月亮被“吃掉”一半，包括北京在内的东部地区将在此前后迎来带食月升。19时04分食既，月亮完全进入本影，红月亮取代满月，夜空重归暗色，被满月光辉掩盖的恒星们也将一一显现。食甚发生在19时33分，月亮最暗，之后月亮将越来越亮。20时02分生光，全食阶段结束，月亮开始重新显露白色光芒。http://finance.sina.com.cn/wm/2026-02-25/doc-inhnzvzh5015146.shtml7、《啤酒史》：一半是绵密的泡沫，一半是惊喜的风味爱酒者，痴迷于酒香美味，入口细品，妙不可言，滴滴难舍。厌恶者，视酒为毒药，听闻之即心生排斥，而且还非常坚决地声明：酒是2012年被WHO列为I类的致癌物，唯恐避之不及。不管你是热爱酒还是讨厌酒，酒是一个神奇的存在。天文学研究表明，早在人类出现之前，酒精（乙醇）等复杂有机分子便已在星际空间和彗星等天体中存在。例如，科学家于2015年首次在洛夫乔伊彗星（C/2014 Q2）上明确探测到乙醇分子，这为研究生命前驱物质在宇宙中的分布提供了直接证据。地球上的酒精有外来者，也有本土自然生成者，而人类所饮用的酒，是经过先民的智慧代代传承创新的成果。《酒精计划》剧照。http://k.sina.com.cn/article_1644114654_61ff32de020023w8m.html8、致114伤1死，中国企业的血糖仪遭FDA警告来源：健识局2月17日，FDA官网发布公告，指出三诺生物旗下产品真睿系列（TRUE METRIX）血糖监测系统存在高风险隐患。FDA指出，发起安全警告的原因是该系列产品使用说明书中对“E-5错误码”的指引存在疏漏。设备显示“E-5错误码”有两种可能，一是测试试纸问题导致的设备误差，二是表示患者的血糖水平超过600mg/dL，这属于危及生命的极高血糖水平，需要立即就医。图源：FDA官网然而，该产品起初的使用说明书只笼统地给出了常规操作建议。FDA认为，这种操作指引缺陷可能导致患者把极高血糖警示作为设备故障。延误就医则会导致患者脱水、精神状态改变，乃至死亡的严重后果。http://finance.sina.com.cn/cj/2026-02-25/doc-inhnzvzh5009847.shtml9、难得一见！拜耳起诉强生来源：健识局因一项真实世界头对头的试验数据，两大跨国药企即将对簿公堂。2月23日，拜耳在美国纽约地方法院正式向强生提起诉讼，指控强生近期针对拜耳治疗前列腺癌的药物达罗他胺（Nubeqa）发起了具有误导性的宣传活动，要求强生纠正宣传内容以消除所带来的负面影响。导火索是强生在2月2日发布的新闻稿。为了证明自己的前列腺癌药物阿帕他胺疗效更好，强生在新闻稿中引用了一项真实世界头对头的回顾性分析：患者使用阿帕他胺，死亡风险比使用拜耳的达罗他胺要降低51%。这一宣传惹恼了拜耳。交涉无果后，拜耳一纸诉状把强生告上了法庭，向法院申请永久禁令，并要求法院判决强生返还其不当利润。http://finance.sina.com.cn/cj/2026-02-25/doc-inhnzvzk2111405.shtml10、复星医药子公司复迈宁新增适应症临床试验获批准（来源：北京商报）北京商报讯（记者 丁宁）2月25日晚间，复星医药（600196）发布公告称，公司控股子公司上海复星医药产业发展有限公司（以下简称“复星医药产业”）收到国家药品监督管理局关于同意复迈宁（通用名：芦沃美替尼片）联合安罗替尼用于鼠类肉瘤病毒癌基因（KRAS）突变的晚期非小细胞肺癌（NSCLC）患者开展临床试验的批准。复星医药产业拟于条件具备后于中国境内开展该药品的Ⅱ期临床试验。http://finance.sina.com.cn/jjxw/2026-02-25/doc-inhnzrtn2219907.shtml11、康弘药业KHN707片临床试验获批准（来源：北京商报）北京商报讯（记者 丁宁）2月25日晚间，康弘药业（002773）发布公告称，近日，公司收到国家药品监督管理局签发的《药物临床试验批准通知书》，同意KHN707片开展用于失眠症的临床试验。康弘药业表示，KHN707片是公司自主研发的选择性食欲素2（OX2R）受体拮抗剂，属于化药1类创新药，剂型为片剂。前期已完成的研究结果显示KHN707片安全性较好，且在失眠模型中具有良好的治疗作用，预期临床应用前景较好。http://finance.sina.com.cn/jjxw/2026-02-25/doc-inhnzrtn2219126.shtml12、君实生物与德琪医药达成癌症临床研究合作（来源：抗体圈）2月25日，君实生物宣布与德琪医药达成战略合作，双方将共同探索君实生物自主研发的JS207（抗PD-1/VEGF双特异性抗体）与德琪医药的ATG-037（口服CD73小分子抑制剂）在中国大陆肿瘤患者中的联合治疗协同潜力。JS207是君实生物自主研发的重组人源化抗PD-1和VEGF双特异性抗体，在临床前及临床研究中均显示出令人鼓舞的抗肿瘤活性及可控的安全性特征。临床前研究在多个肿瘤模型中验证了其显著的抗肿瘤疗效，并支持其差异化的作用机制。研究显示，VEGFA可增强JS207的抗原结合活性、T细胞激活效力以及对细胞表面PD-1的内吞作用。http://finance.sina.com.cn/roll/2026-02-25/doc-inhnzrtn2227869.shtml13、466个靶点大数据：CHO细胞生产抗体，这几条路最靠谱（来源：抗体圈）摘要：我梳理了2011-2024年间164篇关于CHO细胞工程的研究，提取466个工程靶点数据后发现，这一领域已从简单的基因过表达转向CRISPR介导的基因敲除，组合工程、核靶点、表观遗传及凋亡/增殖通路改造的增产效果最显著。但多年来产量提升倍数始终稳定，标准化模型和结构化数据集的缺失成了瓶颈，而通路导向的多靶点改造，或许是下一代抗体生产的核心方向。一、CHO细胞，抗体生产的绝对主力生物药里，单克隆抗体是绝对的主力军，而CHO细胞就是生产这些抗体的“王牌工厂”。http://k.sina.com.cn/article_5953466437_162dab0450670a3nzq.html